LEO Pharma Signs US$402 M Dermatology Deal with JW Pharmaceutical
By Michelle Liu & Keval Haria
Pharma Deals Review: Vol 2018 Issue 9 (Table of Contents)
Published: 19 Sep-2018
DOI: 10.3833/pdr.v2018.i9.2360 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Continuing to build its dermatology portfolio, LEO Pharma has entered into a global licensing agreement with JW Pharmaceutical gaining exclusive rights to develop and commercialise an atopic dermatitis drug candidate, JW1601...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS